BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22951235)

  • 1. Introduction: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ; Sclar DA
    J Clin Psychiatry; 2012; 73 Suppl 1():3-4. PubMed ID: 22951235
    [No Abstract]   [Full Text] [Related]  

  • 2. Discussion: a fresh look at monoamine oxidase inhibitors for depression.
    Cohen LJ; Sclar DA; Culpepper L; Flockhart DA; Hirschfeld RM; Thase ME; VanDenBerg CM
    J Clin Psychiatry; 2012; 73 Suppl 1():42-5. PubMed ID: 22951242
    [No Abstract]   [Full Text] [Related]  

  • 3. [MAO-inhibitors--a treatment option for treatment resistant depression: application, efficacy and characteristics].
    Köhler S; Stöver LA; Bschor T
    Fortschr Neurol Psychiatr; 2014 Apr; 82(4):228-36; quiz 237-8. PubMed ID: 24710679
    [No Abstract]   [Full Text] [Related]  

  • 4. Atypical depression. A valid clinical entity?
    Stewart JW; McGrath PJ; Rabkin JG; Quitkin FM
    Psychiatr Clin North Am; 1993 Sep; 16(3):479-95. PubMed ID: 8415233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
    Flockhart DA
    J Clin Psychiatry; 2012; 73 Suppl 1():17-24. PubMed ID: 22951238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of the cardiac-impaired depressed patient. Part I: General considerations, heterocyclic antidepressants, and monoamine oxidase inhibitors.
    Goldstein MG; Guttmacher LB
    Psychiatr Med; 1988; 6(3):1-33. PubMed ID: 3062672
    [No Abstract]   [Full Text] [Related]  

  • 8. N-acetylcysteine augmentation to tranylcypromine in treatment-resistant major depression.
    Carvalho AF; Macêdo DS; Goulia P; Hyphantis TN
    J Clin Psychopharmacol; 2013 Oct; 33(5):719-20. PubMed ID: 23899640
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of monoamine oxidase inhibitors in primary care.
    Culpepper L
    J Clin Psychiatry; 2012; 73 Suppl 1():37-41. PubMed ID: 22951241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depression in medical illness. Workshop report.
    Paykel E
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):205-7. PubMed ID: 8468445
    [No Abstract]   [Full Text] [Related]  

  • 11. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 12. Endogenous depression: biochemical determinants and drug treatment.
    Hollister LE
    Drug Ther; 1982; ():81-98. PubMed ID: 7049653
    [No Abstract]   [Full Text] [Related]  

  • 13. Reversible monoamine oxidase-A inhibitors in resistant major depression.
    Nolen WA; Hoencamp E; Bouvy PF; Haffmans PM
    Clin Neuropharmacol; 1993; 16 Suppl 2():S69-76. PubMed ID: 8313400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine oxidase inhibitors revisited: what you should know.
    Goldberg JF; Thase ME
    J Clin Psychiatry; 2013 Feb; 74(2):189-91. PubMed ID: 23473352
    [No Abstract]   [Full Text] [Related]  

  • 15. Drugs for depression.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
    [No Abstract]   [Full Text] [Related]  

  • 16. Results of the STAR*D study: implications for clinicians and drug developers.
    Preskorn SH
    J Psychiatr Pract; 2009 Jan; 15(1):45-9. PubMed ID: 19182564
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of antidepressants.
    Tamburrino M; Johnson LW
    Am Fam Physician; 1987 Sep; 36(3):236-42. PubMed ID: 3630886
    [No Abstract]   [Full Text] [Related]  

  • 18. New antidepressants and trends in the pharmacotherapy of depressive disorders.
    Zarifian E; Rigal F
    Psychiatr Clin North Am; 1983 Mar; 6(1):129-39. PubMed ID: 6889169
    [No Abstract]   [Full Text] [Related]  

  • 19. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
    Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
    J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression.
    Adli M; Pilhatsch M; Bauer M; Köberle U; Ricken R; Janssen G; Ulrich S; Bschor T
    Pharmacopsychiatry; 2008 Nov; 41(6):252-7. PubMed ID: 19067263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.